Notice of Preliminary Results

RNS Number : 7419C

Epistem Holdings plc

20 October 2015

 

 Epistem Holdings Plc

("Epistem" or "the Company")

Notice of Preliminary Results

20 October 2015

Epistem Holdings Plc (AIM: EHP), the personalised medicine and biotechnology company, will be announcing preliminary results for the year ended 30 June 2015 on Wednesday, 28 October 2015.

An analyst meeting will be held on the day of the results at 9:30am in the Dome Room at 1 Cornhill, London, EC3V 3ND.

For further details please contact:

Epistem Holdings Plc

Dr Ian Gilham: Chairman                                                                                       [phone]

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                              [phone]

Oliver Jackson

Consilium Strategic Communications

Chris Gardner / Laura Thornton                                                                          [phone]

[e-mail] 

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Genedrive® provides a major advance in molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity and specificity for the diagnostics of infectious diseases and for use in patient stratification (genotyping). Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the India sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com 

 

END

 

 

NOREAKENFEFSFFF